A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment

NCT01183598 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Castleman's Disease

Interventions

DRUG: tocilizumab [RoActemra/Actemra]

Sponsor

Hoffmann-La Roche